A novel inhibitor targeting matrix accumulation in fibrosis
Medicine : Therapeutics
Medicine : Animal Models
Nucleic Acid-, Protein and Cell-related Technologies
Scientists of the Max-Planck-Institute of Biochemistry have identified a unique cyclic molecule that diminishes extracellular matrix in fibrotic diseases.
Intraperitoneal application of the molecule in mice afflicted with liver fibrosis not only diminished the collagen amount, it also led to improvement in liver function.
The application did not result in any adverse toxic effect. This molecule is therefore a suitable candidate for therapy of organ fibrosis.
We are looking for a collaboration partner to further develop this exciting project.
EP priority application was filed on 31.07.2019 followed by an international patent application PCT/EP2020/071319 that was filed on 28.07.2020.
- Ref.-No.: 0105-5855_2-IKF (169.8 KiB)
Dr. Ingrid Kapser-Fischer
Phone: +49 89 / 29 09 19-19